Sinovac's vaccine general efficacy less than 60% in Brazil trial - report

A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo

BRASILIA, Jan 11 (Reuters) - The CoronaVac COVID-19 vaccine developed by China's Sinovac Biotech (SVA.O) has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results.

Sao Paulo's Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report "purely speculative." read more

Register now for FREE unlimited access to
Reporting by Anthony Boadle; Editing by Leslie Adler

Our Standards: The Thomson Reuters Trust Principles.